Picard Medical (NYSE American: PMI) said the SynCardia Total Artificial Heart will be featured on BTV on FOX Business Saturday, March 14 at 5:00 p.m. EST. The segment highlights the STAH’s clinical use and the company’s next‑generation fully implantable artificial heart program.
The STAH has supported more than 2,100 implants worldwide and replaces both ventricles and four valves to sustain patients awaiting transplantation; the segment will be available for replay via BTV online.
Loading…
Loading translation…
Total Artificial Heart implants more than 2,100 implants Worldwide SynCardia Total Artificial Heart use
Patients supported more than 2,100 patients Patients supported by SynCardia Total Artificial Heart worldwide
Heart valves replaced 4 heart valves Device replaces both ventricles and all four valves
Broadcast date March 14, 2026 BTV segment airing on FOX Business News
Broadcast time 5:00 p.m. EST Scheduled airtime of BTV segment
$1.29 Last Close
Volume Volume 519,879 is below 20-day average of 2,036,760, suggesting limited participation. low
Technical Shares at 1.29 are trading below the 200-day MA of 2.77 and far under the 13.68 52-week high.
PMI gained 12.17% while key peers were mixed to negative, including CTKB at -1.96% and LAB at -3.61%, indicating a stock-specific reaction.
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Conference data update | Positive | +0.0% | New clinical and preclinical data for SynCardia and Emperor systems at THT 2026. |
| Feb 26 | Training day participation | Positive | -0.9% | Hands-on SynCardia Total Artificial Heart training at THT 2026 conference. |
| Feb 23 | Surgical training event | Positive | -7.1% | Invitation-only surgical training program at Houston Methodist for total artificial heart. |
| Feb 12 | Clinical milestone case | Positive | -1.2% | Successful bridge-to-transplant case at UCSF using SynCardia Total Artificial Heart. |
| Feb 10 | Scientific presentation | Positive | -4.2% | Presentation of Emperor Total Artificial Heart data at European MCS summit. |
Pattern Detected
Operational and clinical updates have generally seen flat to negative next-day moves despite positive tone.
Recent Company History
Over recent months, Picard Medical has repeatedly highlighted SynCardia Total Artificial Heart progress, including training events, clinical milestones, and conference data releases between Feb 10, 2026 and Mar 2, 2026. Those announcements focused on adoption, surgeon training, and early data for the fully implantable Emperor system, yet 24-hour price reactions were flat or negative. Today’s BTV/FOX Business exposure continues the communication push around the same core platform and next‑generation technology.
This announcement expands Picard Medical’s communication push by showcasing the SynCardia Total Artificial Heart and a fully implantable next‑generation platform on an investment‑focused BTV segment airing via FOX Business News. It reinforces prior clinical and training updates while emphasizing more than 2,100 implants worldwide. Investors may track how increased awareness interacts with recent SEC filings that outline larger authorized share counts and up to 17,000,000 registered resale shares, which frame capital structure and dilution risk.
total artificial heart medical
“maker of the world’s first total artificial heart approved by both the U.S.”
A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.
biventricular heart failure medical
“restoring circulation in patients with severe biventricular heart failure who are at risk”
Biventricular heart failure is a condition where both the right and left sides of the heart are weakened and cannot pump blood effectively, like a two-pump system losing power on both ends. It matters to investors because it increases demand for treatments, medical devices, hospital care and long-term therapies, can drive clinical-trial activity and regulatory decisions, and may affect costs and revenue for companies in cardiovascular drugs, devices and healthcare services.
mechanical circulatory support medical
“at risk of imminent death without mechanical circulatory support.”
Mechanical circulatory support are medical devices that help or take over the heart’s job of moving blood around the body, ranging from temporary external pumps to implanted pumps that assist one or both sides of the heart. For investors, these devices matter because their use drives sales, regulatory scrutiny, reimbursement decisions and long‑term healthcare costs; think of them as a backup engine for a failing heart whose adoption and outcomes influence a company’s market opportunity and risk profile.
pneumatic drivers technical
“fully implantable artificial heart platform designed to improve patient mobility … by eliminating external pneumatic drivers.”
Pneumatic drivers are handheld or bench-mounted tools that use compressed air to turn, drive or tighten fasteners and other components, similar to how a wind-up toy uses stored energy to move. For investors, they matter because they are common capital equipment in factories, construction and maintenance: the choice, quality and availability of these tools affects production speed, labor costs, maintenance spending and workplace safety, which in turn influence operating margins and capital expenditure plans.
AI-generated analysis. Not financial advice.
Segment showcases SynCardia Total Artificial Heart supporting patients with advanced heart failure and next-generation development programs
TUCSON, Ariz., March 13, 2026 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that the SynCardia Total Artificial Heart (“STAH”) will be featured in an upcoming segment on BTV Business Television airing on the FOX Business News on Saturday, March 14 at 5:00 p.m. EST.
The segment will highlight the Company artificial heart technology designed to replace the pumping function of a failing human heart during the time that a patient awaits transplantation.
With more than 2,100 implants performed worldwide, the STAH remains the most widely used and extensively studied artificial heart technology globally. The device is considered a “total” replacement since it replaces both left and right ventricles and all four heart valves, restoring circulation in patients with severe biventricular heart failure who are at risk of imminent death without mechanical circulatory support.
The segment will also highlight the Company’s development of a next-generation, fully implantable artificial heart platform designed to improve patient mobility and quality of life by eliminating external pneumatic drivers.
“We believe raising awareness of advanced heart failure therapies is increasingly important as the number of patients in need of mechanical circulatory support continues to grow,” said Patrick N.J. Schnegelsberg, Chief Executive Officer of Picard Medical. “The SynCardia Total Artificial Heart has supported more than 2,100 patients worldwide by replacing the pumping function of a failing heart and providing critical time for patients awaiting transplantation. We are also advancing the next generation of artificial heart technology designed to further improve patient mobility and quality of life.”
BTV – Business Television is a long running investment focused television program that profiles emerging companies and technologies across a range of industries. The program airs across major financial networks and digital platforms and provides companies with exposure to retail and institutional investor audiences.
The Picard Medical segment will also be available via replay through BTV’s online distribution channels following the broadcast: http://www.b-tv.com/post/picard-medical-advancing-total-artificial-heart-technology-btv-feature.
About BTV – Business Television / BTV The Agency
For 28 years, BTV – Business Television has been on the air as the go-to half-hour investment show for savvy investors, delivering exclusive on-location interviews and actionable insights with emerging companies, industry leaders, and market experts. Hosted by Taylor Thoen and Jessica Katrichak, BTV provides investors with direct access to executive teams and compelling investment opportunities not found anywhere else. BTV The Agency is a capital markets–focused B2B TV production and digital marketing agency serving publicly traded and financial companies. Through strategic content creation and extensive distribution across top-tier networks including Bloomberg, CNBC, FOX Business News, and leading financial platforms, the agency helps companies reach investors, advisors, and institutions—building brand credibility and driving national retail and institutional investor awareness.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the circulatory functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ
When will Picard Medical (PMI) appear on BTV on FOX Business?
Picard Medical will be featured on BTV on FOX Business on Saturday, March 14 at 5:00 p.m. EST. According to the company, the segment will profile the SynCardia Total Artificial Heart and be available for online replay after broadcast.
How many patients has the SynCardia Total Artificial Heart (PMI) supported worldwide?
The SynCardia Total Artificial Heart has supported more than 2,100 patients worldwide. According to the company, that figure reflects cumulative implants and underscores the device’s long clinical use for patients awaiting transplant.
What does the SynCardia Total Artificial Heart (PMI) replace in patients with advanced heart failure?
The STAH replaces both ventricles and all four heart valves to restore circulation in severe biventricular failure. According to the company, it provides mechanical circulatory support for patients awaiting heart transplantation.
What is Picard Medical (PMI) developing beyond the current SynCardia Total Artificial Heart?
Picard Medical is developing a next‑generation, fully implantable artificial heart platform to eliminate external pneumatic drivers. According to the company, this aims to improve patient mobility and quality of life versus external driver systems.
Where can investors watch the Picard Medical (PMI) BTV segment after the FOX Business airing?
The BTV segment will be available for replay via BTV’s online distribution channels at BTV’s website. According to the company, the segment will remain accessible through BTV’s digital platforms following the broadcast.
